Navigation Links
Childhood cancer survivors show sustained benefit from common ADHD medication
Date:9/13/2010

A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children's Research Hospital investigators.

Researchers reported that one year after starting the drug methylphenidate, young cancer survivors scored better on tests of sustained attention and other measures of attention, social skills and behavior than did a similar group of unmedicated survivors. While taking methylphenidate, scores on the attention and behavior measures of many survivors returned to normal ranges. Methylphenidate is marketed under several brand names, including Ritalin and Concerta. The study is the first to document that some survivors enjoy long-term benefits from its use.

Coupled with results from earlier medication side effects studies, the study's authors said these findings offer hope and reassurance for survivors, their families and others looking for ways to ease such late effects of cancer and its treatment. The work appears in the September 13 online edition of the Journal of Clinical Oncology.

"We found that methylphenidate improves both attention and social skills and that these benefits are maintained," said Heather Conklin, Ph.D., assistant member of the St. Jude Department of Psychology and the study's first author. "Although the drug did not lead to a significant gain in measured academic skills, many parents reported their children's grades improved because the children did a better job of managing tasks like planning ahead for projects or remembering to complete and turn in assignments."

The results come as the growing ranks of childhood cancer survivors have the pediatric cancer community searching for better ways to ease or even prevent treatment late effects.

Conklin said the findings also underscore the need for non-pharmacological approaches. Earlier research from Conklin and her colleagues found only about half of young cancer survivors benefit from methylphenidate. Also, Conklin said many parents are reluctant to use the drug and some survivors may not be good candidates due to medical or other reasons. "We are moving forward with research into new strategies to benefit more survivors and their families," she said.

This study focused on young survivors of brain tumors and acute lymphoblastic leukemia (ALL). Their cancer treatment included surgery, radiation and/or chemotherapy targeting the central nervous system. Those treatments and other factors, including a patient's age at treatment, are linked to risk of later attention, memory and processing speed problems that make learning difficult. Such troubles can reverberate through life and affect a survivor's ability to hold a job and live independently.

Although methylphenidate has been used successfully for decades to treat ADHD in healthy children, Conklin said that was no guarantee the drug would benefit children whose symptoms followed a cancer diagnosis. Excluded from this study were children who had ADHD before their cancer was found.

After a year of methylphenidate, young cancer survivors scored better on tests of sustained attention. Parent, teacher and survivor ratings of attention all improved. Parental ratings of social skills and behavior problems also documented that survivors had benefited. The group included 35 brain tumor and 33 ALL survivors.

In contrast, only parental ratings of attention and social skills improved during the same period for a similar group of survivors not taking medication. The group included 31 brain tumor and 23 ALL survivors.

Academic skills measured by completion of math, reading and spelling problems were not significantly better in either group. Conklin said that might reflect the study design, which did not assess changes in executive aspects of school performance, including organization and planning.


'/>"/>

Contact: Summer Freeman
summer.freeman@stjude.org
901-595-3061
St. Jude Children's Research Hospital
Source:Eurekalert

Related medicine news :

1. NASBE Supports First Lady Michelle Obama in Fight Against Childhood Obesity
2. Childhood obesity: Its not the amount of TV, its the number of junk food commercials
3. Planting Seeds to Fight Childhood Obesity
4. PolicyLink CEO Angela Glover Blackwell Released the Following Statement on First Lady Michelle Obamas Childhood Obesity Initiative
5. AMA Joins First Lady in Fight Against Childhood Obesity
6. Soothing infants with food focus of childhood obesity study
7. In Support of the Lets Move Campaign to Fight Childhood Obesity, Verizon Thinkfinity Providing Free Educational Resources on Nutrition and Exercise
8. The Alliance for a Healthier Generation Names Celtics Captain Paul Pierce National Athlete Spokesperson in the Fight Against Childhood Obesity
9. New therapeutic target for most common solid cancer in childhood?
10. High Rates of Childhood Leukemia Seen in Iraq Province
11. International study confirms doubling of childhood leukemia rates in southern Iraq
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “To Walk ... radioman on a B17 bomber named Edward Koontz. “To Walk Away” is the creation ... Scranton, who has published over two hundred manuscripts in chemistry and religion, as well ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery and ... author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent most ... “Love is one of the least understood and yet most sought-after pleasures known to ...
(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is ... many communities have begun providing weekend displays, and numerous households celebrate the unofficial end ... can be downright terrifying for pets. , Kris Zambo, owner of Dynamite ...
(Date:8/21/2017)... Los Angeles, California (PRWEB) , ... August 21, ... ... Physicians is announcing the addition of two plastic surgery fellows for academic year ... is designed for candidates who have successfully completed residency in Plastic and Reconstructive ...
(Date:8/21/2017)... Milwaukee, WI (PRWEB) , ... August 21, 2017 ... ... recent years, with events taking place all over the country. , Outdoor running ... that marathon runners are at an increased risk of melanoma, and only half ...
Breaking Medicine News(10 mins):
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/31/2017)... -- 7D Surgical, developer of ground breaking surgical navigation technologies, ... System to support its strategic sales plan in ... Virginia.  7D Surgical has entered into an exclusive sales representative ... facilities within those markets. ... Spartan Medical Purchases 7D ...
(Date:7/27/2017)... July 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... ended June 30, 2017.  The Company reported second quarter ... over the prior year period, and an increase of ... basis points of contribution from the LDR Holding Corporation ... second quarter of 2016, or 0.3% on a constant ...
Breaking Medicine Technology: